Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03740724
Other study ID # FI-SC-001
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date December 18, 2019
Est. completion date April 21, 2022

Study information

Verified date January 2024
Source Castle Creek Biosciences, LLC.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A two-component therapeutic consisting of FCX-013 and veledimex for the treatment of localized scleroderma (or morphea). The first component, FCX-013, is autologous human fibroblasts genetically-modified using lentivirus and encoded for matrix metalloproteinase 1 (MMP-1), a protein responsible for breaking down collagen. FCX-013 is designed to be injected under the skin at the location of the fibrotic lesions where the genetically-modified fibroblast cells will produce MMP-1 to break down excess collagen accumulation. With the FCX-013 therapy, the patient will take an oral compound (Veledimex) to induce MMP-1 protein expression from the injected cells. Once the fibrosis is resolved, the patient will stop taking the oral compound which will stop further MMP-1 production from the injected cells. FCX-013 plus veledimex is being developed in anticipation of improving skin function in patients by resolving fibrotic lesions and normalizing dermal collagen production


Description:

Castle Creek is developing a two-component therapeutic product for the treatment of moderate to severe localized scleroderma (morphea). The first component is FCX-013, an autologous genetically modified human dermal fibroblast (GM-HDFs) cell product that is genetically modified with a lentiviral vector (LV) to express human matrix metalloproteinase 1 (MMP1). MMP1 is also known as interstitial collagenase or fibroblast collagenase and is an enzyme that under normal physiological conditions breaks down the extracellular matrix. Specifically, MMP1 breaks down interstitial collagens, types I, II and III. In addition, the FCX-013 cells are also transduced with genetic constructs that encode the RheoSwitch Therapeutic System® (RTS®) an inducible promotor system that in the presence of a small molecule activator ligand controls expression of the MMP1 gene. The RTS® is activated to express MMP1 by the oral administration of the small molecule component. The purpose of this open-label single arm Phase 1/2 study is to investigate the safety and effectiveness of FCX-013 plus veledimex.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date April 21, 2022
Est. primary completion date September 23, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject is an adult, = 18 years of age with moderate to severe localized scleroderma/morphea with sclerotic lesions which have been unresponsive to standard of care therapy. - Subject has stable control of localized disease (clinically inactive) over the 3 months prior to Screening and through Baseline - Subject has not participated in previous clinical research study in the 3 months prior to Screening and through Baseline - Subject has provided informed written consent - Female subjects of childbearing potential and male subjects engaging in sexual activity that could lead to pregnancy agree to use adequate birth control regimen - Subject is able to understand the study, cooperate with the study procedures and willing to return to the clinic for the required follow-up visits Exclusion Criteria: - Subject has a clinically significant skin disorder other than localized scleroderma/morphea in the anatomical area of interest - Subject has localized scleroderma/morphea only located on the face or over a joint, or lesions that can be successfully managed with topical medications or phototherapy - Subject has symptoms consistent with systemic scleroderma that have not been stable, or that require treatment that has not been stable for 3 months prior to Screening and through Baseline - Subject has been treated with UVA1 phototherapy within 2 months prior to Baseline - Subject requires treatment with a non-stable regimen of systemic immunosuppressive therapy, for any medical condition, or plans to initiate such treatment during the study period - Subject requires treatment with a non-stable regimen of physical therapy, for localized scleroderma/morphea, or plans to initiate such treatment during the study period. - Subject has any medical instability limiting ability to travel to the investigative center. - Subject has clinical signs of infection at (or in close proximity to) the target lesion. - Subject has a history of, or current, malignancy at/near site of injection (except basal cell carcinoma or squamous cell carcinoma that have been treated) - Subject has a history of, or current, clinically significant liver abnormalities. - Subject has a history of, or current, clinically significant cardiac abnormalities, or a significant abnormality on ECG - Subject has clinically significant laboratory abnormalities - Subject has active infection with human immunodeficiency virus (HIV), or hepatitis B/C - Subject has an active drug or alcohol addiction - Subject has any known allergy to any of the constituents of the product - Subject has received an interventional chemical or biological investigational study product for the specific treatment of localized scleroderma in the 3 months prior to Screening and through Baseline - Subject is pregnant or nursing or plans to become pregnant or nurse during the study period

Study Design


Intervention

Genetic:
FCX-013
FCX-013 is a genetically modified cell product obtained from the subject's own skin cells (autologous fibroblasts). The cells are expanded and genetically modified to express metalloproteinase-1 (MMP-1) under the control of a RheoSwitch (RTS®) system. FCX-013 cell suspension is injected intradermally.
Drug:
veledimex
Veledimex, is a small molecule which activates the RTS to induce expression of MMP-1 and is and provided as a liquid filled gelatin capsule for oral administration

Locations

Country Name City State
United States Paddington Testing Co., Inc. Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Castle Creek Biosciences, LLC.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the Safety of FCX-013 Plus Veledimex Safety evaluations include assessment of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs); change in clinical laboratory values; change in vital signs; change in electrocardiograms (ECGs); and incidence of replication-competent lentivirus (RCL) antibodies. Study initiation through study completion
Secondary Evaluate the Antifibrotic Effects of FCX-013 Plus Veledimex Evaluate the antifibrotic effects of FCX-013 plus veledimex Week 4
See also
  Status Clinical Trial Phase
Completed NCT02798055 - Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
Completed NCT01959815 - Novel Screening Strategies for Scleroderma PAH
Completed NCT03274076 - Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Phase 1/Phase 2
Completed NCT02915835 - Riociguat in Scleroderma Associated Digital Ulcers Phase 2
Active, not recruiting NCT01895244 - Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis Phase 2
Completed NCT00930683 - A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma Phase 1
Completed NCT00883129 - Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Phase 2
Completed NCT00074568 - Scleroderma Registry
Recruiting NCT04797286 - Sildenafil for Early Pulmonary Vascular Disease in Scleroderma Phase 2
Completed NCT03222492 - Brentuximab Vedotin for Systemic Sclerosis Phase 1/Phase 2
Completed NCT03207997 - MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients N/A
Recruiting NCT04464434 - Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis Phase 4
Recruiting NCT04246528 - SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF) N/A
Completed NCT05080738 - Upper Extremity Home Exercises in Patients With Scleroderma N/A
Recruiting NCT03726398 - CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH Phase 2/Phase 3
Recruiting NCT05085444 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma Early Phase 1
Completed NCT02062125 - Calcinosis in a Single-Center Scleroderma Population
Completed NCT04588714 - Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention N/A
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT02835196 - Optical Elastography of Systemic Sclerosis Skin